FDX1 was differently expressed in most cancer and its expression was associated with immune characteristics and other tumor characteristics including Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), Mismatch Repair (MMR), and DNA methyltransferase (DNMT) in pan-cancer. Here, DNMT1 is linked to neoplasm.